Emilio Esteban

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3822669/publications.pdf

Version: 2024-02-01

132 papers	9,763 citations	236925 25 h-index	38395 95 g-index
139 all docs	139 docs citations	139 times ranked	11734 citing authors

#	Article	IF	Citations
1	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European Urology Oncology, 2021, 4, 502-505.	5.4	5
2	PTEN expression and mutations in TSC1 , TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. International Journal of Cancer, 2020, 146, 1435-1444.	5.1	14
3	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 1505-1517.	1.6	710
4	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 387-397.	10.7	119
5	Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. Cancer Chemotherapy and Pharmacology, 2019, 84, 781-789.	2.3	3
6	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. Advances in Therapy, 2019, 36, 1497-1508.	2.9	4
7	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
8	Radium-223 international early access program: results from the Spanish subset. Future Oncology, 2018, 14, 41-50.	2.4	3
9	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptorâ€“Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	1.9	20
10	Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Expert Opinion on Drug Safety, 2018, 17, 573-579.	2.4	3
11	KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology, 2018, 29, ix164.	1.2	0
12	PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology, 2018, 13, S155.	1.1	0
13	230P Experience with the implant of vascular access devices by medical oncologists in a non-surgical setting. Journal of Thoracic Oncology, 2018, 13, S137-S138.	1.1	0
14	Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. Cancer Research, 2018, 78, CT075-CT075.	0.9	6
15	CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?. Clinical and Translational Oncology, 2017, 19, 105-110.	2.4	0
16	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Scientific Reports, 2017, 7, 41371.	3.3	3
17	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	4.4	22
18	Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting. Advances in Therapy, 2017, 34, 136-147.	2.9	8

#	Article	IF	Citations
19	Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. Journal of Translational Medicine, 2017, 15, 62.	4.4	6
20	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus, 2017, 3, 280-286.	3.1	2
21	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01). European Urology Focus, 2017, 3, 430-436.	3.1	4
22	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 4635-4643.	2.0	10
23	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2017, 8, 30410-30421.	1.8	19
24	Predictors of radiologic progression free survival (rPFS) during abiraterone acetate (AA) treatment in a randomized phase II study of AA maintenance in combination with docetaxel (D) after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2017, 35, e16536-e16536.	1.6	0
25	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 822-835.	10.7	390
26	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports, 2016, 18, 66.	4.0	6
27	Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2016, 27, vi285.	1.2	1
28	Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer, 2016, 16, 135.	2.6	7
29	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Targeted Oncology, 2016, 11, 129-141.	3.6	3
30	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight, 2016, 1, e86051.	5.0	39
31	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2016, 34, 5058-5058.	1.6	0
32	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2016, 34, e16129-e16129.	1.6	0
33	Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC.. Journal of Clinical Oncology, 2016, 34, e16080-e16080.	1.6	0
34	2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. European Journal of Cancer, 2015, 51, S488.	2.8	0
35	2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. European Journal of Cancer, 2015, 51, S489.	2.8	2
36	2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain. European Journal of Cancer, 2015, 51, S488-S489.	2.8	0

#	Article	IF	Citations
37	Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. Future Oncology, 2015, 11, 1665-1674.	2.4	6
38	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer, 2015, 112, 1190-1198.	6.4	35
39	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiology, 2015, 39, 291-297.	1.9	39
40	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urology, 2015, 15, 15.	1.4	1
41	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. Future Oncology, 2015, 11, 267-277.	2.4	17
42	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatmentâ€"ABIDO-SOGUG Trial.. Journal of Clinical Oncology, 2015, 33, e16022-e16022.	1.6	1
43	Metabolic syndrome (MetS) incidence in renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology, 2015, 33, e15587-e15587.	1.6	0
44	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
45	Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opinion on Drug Safety, 2014, 13, 1165-1173.	2.4	25
46	Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). Investigational New Drugs, 2014, 32, 377-381.	2.6	4
47	Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 760-767.	1.6	331
48	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 286-296.	10.7	239
49	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathwayâ€"targeted therapy and one prior mTOR inhibitor therapy.. Journal of Clinical Oncology, 2014, 32, 473-473.	1.6	1
50	Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 537-537.	1.6	0
51	Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience.. Journal of Clinical Oncology, 2014, 32, 235-235.	1.6	0
52	Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.. Journal of Clinical Oncology, 2014, 32, e16088-e16088.	1.6	0
53	Prospective assessment of circulating endothelial cells (CECs) as markers of activity of first-line treatment in advanced clear cell renal cell carcinoma (CCRCC): The CIRCLES study (SOGUG 2011-01).. Journal of Clinical Oncology, 2014, 32, e22019-e22019.	1.6	0
54	Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study).. Journal of Clinical Oncology, 2014, 32, 4578-4578.	1.6	0

#	Article	IF	Citations
55	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. Journal of Clinical Oncology, 2014, 32, TPS5096-TPS5096.	1.6	0
56	Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Annals of Oncology, 2013, 24, 2409-2414.	1.2	73
57	Fate of Shiga Toxin--Producing O157:H7 and Non-O157:H7 Escherichia coli Cells within Refrigerated, Frozen, or Frozen Then Thawed Ground Beef Patties Cooked on a Commercial Open-Flame Gas or a Clamshell Electric Grill. Journal of Food Protection, 2013, 76, 1500-1512.	1.7	21
58	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. British Journal of Cancer, 2013, 109, 121-130.	6.4	19
59	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. British Journal of Cancer, 2013, 108, 2565-2572.	6.4	31
60	Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first-line setting: The Circles study (SOGUG 2011-01).. Journal of Clinical Oncology, 2013, 31, 436-436.	1.6	0
61	Latex Agglutination Assays for Detection of Non-O157 Shiga Toxinâ€“Producing Escherichia coli Serogroups O26, O45, O103, O111, O121, and O145â€. Journal of Food Protection, 2012, 75, 819-826.	1.7	19
62	Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Investigational New Drugs, 2012, 30, 2443-2449.	2.6	20
63	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncology, The, 2012, 13, 300-308.	10.7	360
64	Prognostic Factors in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2012, 10, 262-270.	1.9	29
65	Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer and Metastasis Reviews, 2012, 31, 33-39.	5.9	11
66	Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treatment Reviews, 2012, 38, 431-441.	7.7	12
67	Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.. Journal of Clinical Oncology, 2012, 30, e15149-e15149.	1.6	3
68	Protein BIII-tubulin expression as a prognostic and/or predictive factor of response to docetaxel in patients with hormone-refractory prostate cancer.. Journal of Clinical Oncology, 2012, 30, 84-84.	1.6	0
69	Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opinion on Pharmacotherapy, 2011, 12, 2433-2439.	1.8	4
70	7161 POSTER Prognostic Factors in Patients With Advanced Renal Cell Carcinoma. European Journal of Cancer, 2011, 47, S523.	2.8	0
71	8048 POSTER Dose Finding Study of Carboplatin in First Line Chemotherapy in Advanced Ovarian Cancer. European Journal of Cancer, 2011, 47, S541.	2.8	0
72	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	10.7	217

#	Article	IF	Citations
73	88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY. Lung Cancer, 2011, 71, S44.	2.0	3
74	Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study. International Journal of Gynecological Cancer, 2011, 21, 478-485.	2.5	8
75	Activity of topotecan given intravenously for 5Âdays every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Investigational New Drugs, 2011, 29, 1459-1464.	2.6	5
76	First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study. Annals of Oncology, 2011, 22, 924-930.	1.2	74
77	Prognostic factors for response to systemic treatments carried out in patients with advanced renal carcinoma.. Journal of Clinical Oncology, 2011, 29, 369-369.	1.6	28
78	Prognostic factors in patients with advanced renal carcinoma.. Journal of Clinical Oncology, 2011, 29, 391-391.	1.6	0
79	Predictive factors for response to systemic treatments carried out in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2011, 29, e15014-e15014.	1.6	0
80	Prognostic factors in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2011, 29, e15011-e15011.	1.6	0
81	Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.. Journal of Clinical Oncology, 2011, 29, 4559-4559.	1.6	0
82	Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clinical and Translational Oncology, 2010, 12, 562-567.	2.4	4
83	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews, 2010, 29, 1-10.	5.9	3
84	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer and Metastasis Reviews, 2010, 29, 11-20.	5.9	3
85	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2010, 11, 521-529.	10.7	1,158
86	Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.. Journal of Clinical Oncology, 2010, 28, LBA4518-LBA4518.	1.6	104
87	Role of the p38Î±MAPK in the prognosis and prediction of response to neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2010, 28, e21073-e21073.	1.6	0
88	Professional burnout among Spanish medical oncologists. Clinical and Translational Oncology, 2009, 11, 86-90.	2.4	7
89	Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis. Cancer Immunology, Immunotherapy, 2009, 58, 235-245.	4.2	0
90	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1-13.	2.3	10

#	Article	IF	Citations
91	Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treatment Reviews, 2009, 35, 364-373.	7.7	26
92	102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT). Lung Cancer, 2009, 64, S45.	2.0	1
93	143P CISPLATINUM PLUS DOCETAXEL (CD) AS INDUCTION CHEMOTHERAPY PRIOR TO RADICAL LOCOREGIONAL (LR) TREATMENT FOR PATIENTS (PTS) WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS OF A PROSPECTIVE PHASE II STUDY. Lung Cancer, 2009, 64, S59.	2.0	0
94	8051 Final results of a phase I study of pegylated liposomal doxorubicin + gemcitabine in prolonged infusion in patients with recurrent ovarian cancer less than one year. European Journal of Cancer, Supplement, 2009, 7, 464.	2.2	0
95	Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Investigational New Drugs, 2008, 26, 67-74.	2.6	22
96	Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy. Clinical and Translational Oncology, 2008, 10, 426-432.	2.4	3
97	Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology, 2007, 18, 1359-1362.	1.2	54
98	Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anti-Cancer Drugs, 2007, 18, 291-296.	1.4	16
99	Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Nonâ€“Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy. Journal of Clinical Oncology, 2007, 25, 3448-3455.	1.6	129
100	6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic. European Journal of Cancer, Supplement, 2007, 5, 361.	2.2	4
101	Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study. Lung Cancer, 2007, 55, 173-180.	2.0	7
102	Oral Vinorelbine. Drugs, 2007, 67, 657-667.	10.9	16
103	B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. Journal of Thoracic Oncology, 2007, 2, S334-S335.	1.1	4
104	Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemotherapy and Pharmacology, 2007, 59, 251-259.	2.3	26
105	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British Journal of Cancer, 2006, 94, 1797-1802.	6.4	2
106	Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 840, 44-49.	2.3	31
107	Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study. Investigational New Drugs, 2006, 24, 241-248.	2.6	14
108	Binational study of pediatric blood lead levels along the United States/Mexico border. International Journal of Hygiene and Environmental Health, 2006, 209, 235-240.	4.3	6

#	Article	IF	Citations
109	Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination. Investigational New Drugs, 2005, 23, 597-601.	2.6	0
110	O-113 Cisplatin plus gemcitabine with or without vinorelbine asneo-adjuvant therapy for radically treatable stage III Non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo OncolÃ³gico del Norte de EspaÃ±a). Lung Cancer, 2005, 49, S40.	2.0	2
111	P-482 Activity of topotecan in patients with advanced non-small cell lung cancer pre-treated with platinum and taxanes: Results of the first analysis. Lung Cancer, 2005, 49, S243.	2.0	0
112	P-641 Concurrent 70 gy thoracic radiotherapy with weekly docetaxel orpaclitaxel after induction chemotherapy in patients with locally advanced non-small-cell lung cancer: Tolerance and efficacy from a non-randomized study. Lung Cancer, 2005, 49, S287.	2.0	0
113	Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases. Journal of Clinical Oncology, 2005, 23, 4756-4756.	1.6	0
114	Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer, 2004, 101, 2261-2269.	4.1	18
115	Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study. Breast Cancer Research and Treatment, 2003, 80, 257-265.	2.5	2
116	Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Investigational New Drugs, 2003, 21, 459-463.	2.6	13
117	Irinotecan in the Treatment of Advanced Colorectal Cancer in Patients Pretreated With Fluorouracil-Based Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 107-111.	1.3	7
118	Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Investigational New Drugs, 2002, 20, 73-82.	2.6	14
119	Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer. Investigational New Drugs, 2002, 20, 317-326.	2.6	5
120	High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma. Cancer, 2001, 92, 2508-2516.	4.1	8
121	Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer, 2000, 88, 162-168.	4.1	62
122	A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Research and Treatment, 2000, 62, 127-133.	2.5	5
123	Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Research and Treatment, 1999, 58, 141-150.	2.5	10
124	362 Aminoglutethimide + hidrocortisone (AMG + HC) vs. megestrol acetate (MEG) as second and third line treatment in advanced breast cancer (ABC): A phase III study. European Journal of Cancer, 1995, 31, S79.	2.8	0
125	Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer. European Journal of Cancer, 1994, 30, 1206-1207.	2.8	3
126	Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma. European Journal of Cancer, 1993, 29, 1354.	2.8	3

#	Article	IF	Citations
127	Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer. European Journal of Cancer, 1992, 28, 242.	2.8	4
128	Dacarbazine in advanced squamous cell carcinoma of the head and neck. European Journal of Cancer & Clinical Oncology, 1991, 27, 215-216.	0.7	0
129	Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Annals of Oncology, 1991, 2, 151-152.	1.2	19
130	Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer. Annals of Oncology, 1991, 2, 521.	1.2	9
131	Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial. Annals of Oncology, 1991, 2, 751-754.	1.2	86
132	The trans-activating C-type retroviruses share a distinct epitope(s) that induces antibodies in certain infected hosts. Journal of General Virology, 1991, 72, 2113-2119.	2.9	17